Header Logo
Keywords
Last Name
Institution
Announcement

You can now add alternative names! Click here to add other names that you've published under.
 Back to Details

Connection

Jeffrey Montgomery to Carcinoma, Transitional Cell

This is a "connection" page, showing publications Jeffrey Montgomery has written about Carcinoma, Transitional Cell.

 
Connection Strength
  
 
 
2.667
  
  1. Montgomery JS. Editorial comment for Sim et al. J Endourol. 2015 Apr; 29(4):390.
    View in: PubMed
    Score: 0.455
  2. Ambani SN, Weizer AZ, Wolf JS, He C, Miller DC, Montgomery JS. Matched comparison of robotic vs laparoscopic nephroureterectomy: an initial experience. Urology. 2014 Feb; 83(2):345-9.
    View in: PubMed
    Score: 0.425
  3. Montgomery JS, Weizer AZ, Montie JE. Editorial comment. Perioperative mortality is significantly greater in septuagenarian and octogenarian patients treated with radical cystectomy for urothelial carcinoma of the bladder. Urology. 2011 Mar; 77(3):667-8.
    View in: PubMed
    Score: 0.351
  4. Wolf JS, Dash A, Hollenbeck BK, Johnston WK, Madii R, Montgomery JS. Intermediate followup of hand assisted laparoscopic nephroureterectomy for urothelial carcinoma: factors associated with outcomes. J Urol. 2005 Apr; 173(4):1102-7.
    View in: PubMed
    Score: 0.233
  5. Kirk PS, Lotan Y, Zargar H, Fairey AS, Dinney CP, Mir MC, Krabbe LM, Cookson MS, Jacobson NE, Montgomery JS, Vasdev N, Yu EY, Xylinas E, Kassouf W, Dall'Era MA, Sridhar SS, McGrath JS, Aning J, Shariat SF, Thorpe AC, Morgan TM, Holzbeierlein JM, Bivalacqua TJ, North S, Barocas DA, Grivas P, Garcia JA, Stephenson AJ, Shah JB, Daneshmand S, Spiess PE, van Rhijn BWG, Mertens L, Black P, Wright JL. Impact of Maximal Transurethral Resection on Pathological Outcomes at Cystectomy in a Large, Multi-institutional Cohort. J Urol. 2023 05; 209(5):882-889.
    View in: PubMed
    Score: 0.201
  6. Flaig TW, Spiess PE, Abern M, Agarwal N, Bangs R, Boorjian SA, Buyyounouski MK, Chan K, Chang S, Friedlander T, Greenberg RE, Guru KA, Herr HW, Hoffman-Censits J, Kishan A, Kundu S, Lele SM, Mamtani R, Margulis V, Mian OY, Michalski J, Montgomery JS, Nandagopal L, Pagliaro LC, Parikh M, Patterson A, Plimack ER, Pohar KS, Preston MA, Richards K, Sexton WJ, Siefker-Radtke AO, Tollefson M, Tward J, Wright JL, Dwyer MA, Cassara CJ, Gurski LA. NCCN Guidelines? Insights: Bladder Cancer, Version 2.2022. J Natl Compr Canc Netw. 2022 08; 20(8):866-878.
    View in: PubMed
    Score: 0.194
  7. Mannan R, Taylor AS, Spratt DE, Chinnaiyan AM, Montgomery JS, Brown NA, Mehra R. TERT- beyond the territory: Usage of PCR-based TERT promoter assay in defining urothelial carcinoma in a case of long-standing prostatic adenocarcinoma. Pathol Res Pract. 2020 Jan; 216(1):152663.
    View in: PubMed
    Score: 0.159
  8. Simon CT, Skala SL, Weizer AZ, Ambani SN, Chinnaiyan AM, Palapattu G, Hafez K, Magers MJ, Kaffenberger SD, Spratt DE, Montgomery JS, Morgan TM, Udager AM, Lew M, Mehra R. Clinical utility and concordance of upper urinary tract cytology and biopsy in predicting clinicopathological features of upper urinary tract urothelial carcinoma. Hum Pathol. 2019 04; 86:76-84.
    View in: PubMed
    Score: 0.150
  9. Brown NA, Lew M, Weigelin HC, Weizer AZ, Montgomery JS, Betz BL, Mehra R. Comparative study of TERT promoter mutation status within spatially, temporally and morphologically distinct components of urothelial carcinoma. Histopathology. 2018 01; 72(2):354-356.
    View in: PubMed
    Score: 0.139
  10. Skala SL, Liu TY, Udager AM, Weizer AZ, Montgomery JS, Palapattu GS, Siddiqui J, Cao X, Fields K, Abugharib AE, Soliman M, Hafez KS, Miller D, Lee CT, Alva A, Chinnaiyan AM, Morgan TM, Spratt DE, Jiang H, Mehra R. Programmed Death-ligand 1 Expression in Upper Tract Urothelial Carcinoma. Eur Urol Focus. 2017 10; 3(4-5):502-509.
    View in: PubMed
    Score: 0.131
  11. McDaniel AS, Zhai Y, Cho KR, Dhanasekaran SM, Montgomery JS, Palapattu G, Siddiqui J, Morgan T, Alva A, Weizer A, Lee CT, Chinnaiyan AM, Quist MJ, Grasso CS, Tomlins SA, Mehra R. HRAS mutations are frequent in inverted urothelial neoplasms. Hum Pathol. 2014 Sep; 45(9):1957-65.
    View in: PubMed
    Score: 0.110
  12. Shah RB, Montgomery JS, Montie JE, Kunju LP. Variant (divergent) histologic differentiation in urothelial carcinoma is under-recognized in community practice: impact of mandatory central pathology review at a large referral hospital. Urol Oncol. 2013 Nov; 31(8):1650-5.
    View in: PubMed
    Score: 0.095
  13. Tan HJ, Jacobs BL, Hafez KS, Montgomery JS, Weizer AZ, Wood DP, Miller DC, Wolf JS. Understanding the role of percutaneous biopsy in the management of patients with a small renal mass. Urology. 2012 Feb; 79(2):372-7.
    View in: PubMed
    Score: 0.023
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.